Christina A Eichstaedt

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1095397/publications.pdf

Version: 2024-02-01

44 papers	2,778 citations	279798 23 h-index	243625 44 g-index
47 all docs	47 docs citations	47 times ranked	4657 citing authors

#	Article	IF	Citations
1	Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. European Respiratory Journal, 2017, 50, 1700740.	6.7	489
2	Genomic analyses inform on migration events during the peopling of Eurasia. Nature, 2016, 538, 238-242.	27.8	360
3	A recent bottleneck of Y chromosome diversity coincides with a global change in culture. Genome Research, 2015, 25, 459-466.	5.5	348
4	BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respiratory Medicine,the, 2016, 4, 129-137.	10.7	307
5	Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects. Human Mutation, 2015, 36, 1113-1127.	2.5	185
6	Genome-Wide Analysis of Cold Adaptation in Indigenous Siberian Populations. PLoS ONE, 2014, 9, e98076.	2.5	128
7	ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension. European Respiratory Journal, 2019, 53, 1800332.	6.7	110
8	Selective sweep on human amylase genes postdates the split with Neanderthals. Scientific Reports, 2016, 6, 37198.	3.3	67
9	The Andean Adaptive Toolkit to Counteract High Altitude Maladaptation: Genome-Wide and Phenotypic Analysis of the Collas. PLoS ONE, 2014, 9, e93314.	2.5	55
10	Therapeutic potential of KLF2-induced exosomal microRNAs in pulmonary hypertension. Nature Communications, 2020, 11, 1185.	12.8	52
11	Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial. European Heart Journal, 2021, 42, 2284-2295.	2.2	51
12	Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. International Journal of Cardiology, 2015, 195, 19-26.	1.7	46
13	Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study). Respiratory Research, 2018, 19, 258.	3.6	39
14	First identification of KrÃ¼ppel-like factor 2 mutation in heritable pulmonary arterial hypertension. Clinical Science, 2017, 131, 689-698.	4.3	38
15	Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study). Arthritis Research and Therapy, 2019, 21, 217.	3.5	34
16	EIF2AK4 mutation as â€œsecond hitâ€•in hereditary pulmonary arterial hypertension. Respiratory Research, 2016, 17, 141.	3.6	33
17	Gender-related differences in pulmonary arterial hypertension targeted drugs administration. Pharmacological Research, 2016, 114, 103-109.	7.1	33
18	Positive selection of AS3MT to arsenic water in Andean populations. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2015, 780, 97-102.	1.0	32

#	Article	IF	Citations
19	Evidence of Early-Stage Selection on EPAS1 and GPR126 Genes in Andean High Altitude Populations. Scientific Reports, 2017, 7, 13042.	3.3	29
20	Bayesian Inference Associates Rare KDR Variants With Specific Phenotypes in Pulmonary Arterial Hypertension. Circulation Genomic and Precision Medicine, 2021, 14, .	3.6	29
21	Pathobiology, pathology and genetics of pulmonary hypertension: Update from the Cologne Consensus Conference 2018. International Journal of Cardiology, 2018, 272, 4-10.	1.7	26
22	Mutation in BMPR2 Promoter: A â€˜Second Hitâ€™ for Manifestation of Pulmonary Arterial Hypertension?. PLoS ONE, 2015, 10, e0133042.	2.5	26
23	Identification of genetic defects in pulmonary arterial hypertension by a new gene panel diagnostic tool. Clinical Science, 2016, 130, 2043-2052.	4.3	25
24	NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD. Nature Metabolism, 2020, 2, 532-546.	11.9	23
25	Exercise Training and Rehabilitation in Pulmonary Hypertension. Heart Failure Clinics, 2018, 14, 425-430.	2.1	21
26	Genetic Predisposition to High-Altitude Pulmonary Edema. High Altitude Medicine and Biology, 2020, 21, 28-36.	0.9	21
27	Genetic and phenotypic differentiation of an Andean intermediate altitude population. Physiological Reports, 2015, 3, e12376.	1.7	18
28	Supervised Exercise Training in Patients with Chronic Thromboembolic Pulmonary Hypertension as Early Follow-Up Treatment after Pulmonary Endarterectomy: A Prospective Cohort Study. Respiration, 2020, 99, 577-588.	2.6	18
29	Gene panel diagnostics reveals new pathogenic variants in pulmonary arterial hypertension. Respiratory Research, 2022, 23, 74.	3.6	18
30	Genetics of pulmonary hypertension and high-altitude pulmonary edema. Journal of Applied Physiology, 2020, 128, 1432-1438.	2.5	15
31	Epigenetic reactivation of transcriptional programs orchestrating fetal lung development in human pulmonary hypertension. Science Translational Medicine, 2022, 14, .	12.4	15
32	Circulating MicroRNA Markers for Pulmonary Hypertension in Supervised Exercise Intervention and Nightly Oxygen Intervention. Frontiers in Physiology, 2018, 9, 955.	2.8	14
33	Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities a cross-sectional cohort study with survival follow-up. Respiratory Research, 2020, 21, 127.	3.6	14
34	Myeloproliferative Diseases as Possible Risk Factor for Development of Chronic Thromboembolic Pulmonary Hypertensionâ€”A Genetic Study. International Journal of Molecular Sciences, 2020, 21, 3339.	4.1	13
35	Mutually reinforcing effects of genetic variants and interferonâ€Î² 1a therapy for pulmonary arterial hypertension development in multiple sclerosis patients. Pulmonary Circulation, 2019, 9, 1-6.	1.7	9
36	Analysis of fullâ€length mitochondrial DNA Dâ€loop sequences from Macaca fascicularis of different geographical origin reveals novel haplotypes. Journal of Medical Primatology, 2015, 44, 125-136.	0.6	6

#	Article	IF	Citations
37	Right Heart Size and Right Ventricular Reserve in Pulmonary Hypertension: Impact on Management and Prognosis. Diagnostics, 2020, 10, 1110.	2.6	6
38	Prognostic impact of hypochromic erythrocytes in patients with pulmonary arterial hypertension. Respiratory Research, 2021, 22, 288.	3.6	6
39	The role of rehabilitation in patients with pulmonary arterial hypertension. Current Opinion in Pulmonary Medicine, 2019, 25, 398-404.	2.6	5
40	BMPR2 Promoter Variants Effect Gene Expression in Pulmonary Arterial Hypertension Patients. Genes, 2020, 11, 1168.	2.4	3
41	The effect of exercise training and physiotherapy on left and right heart function in heart failure with preserved ejection fraction: a systematic literature review. Heart Failure Reviews, 2023, 28, 193-206.	3.9	3
42	Multicentre trials on specialised exercise training and rehabilitation are useful in patients with pulmonary hypertension. European Respiratory Journal, 2019, 54, 1901631.	6.7	2
43	Reduction of BMPR2 mRNA Expression in Peripheral Blood of Pulmonary Arterial Hypertension Patients: A Marker for Disease Severity?. Genes, 2022, 13, 759.	2.4	2
44	The Experience, Prerequisites, and the Barriers in Organizing a Specialized Rehabilitation Program for Patients with Pulmonary Hypertension. Respiration, 2021, 100, 1-9.	2.6	0